共 230 条
[1]
Ferrannini E(2012)Diabetes and hypertension: the bad companions Lancet 380 601-610
[2]
Cushman WC(2011)Hypertension in people with type 2 diabetes: Update on pharmacologic management Can Fam Physician 57 997-1002
[3]
Campbell NR(2008)Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes Int J Clin Pract 62 1279-1284
[4]
Gilbert RE(2014)Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis J Am Soc Hypertens 8 262-275
[5]
Leiter LA(2015)Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial Cardiovasc Diabetol 23 154-372
[6]
Larochelle P(2015)Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial Diabetes Care 38 365-1932
[7]
Tobe S(2014)Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study Cardiovasc Diabetol 13 65-2128
[8]
Chockalingam A(2015)Dapagliflozin lowers plasma glucose concentration and improves beta-cell function J Clin Endocrinol Metab 100 1927-334
[9]
Ward R(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-339
[10]
Morris D(2016)Empagliflozin and progression of kidney disease in type 2 diabetes N Engl J Med 375 323-428